Biopharmaceutical News and Research

RSS

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending time off chemotherapy, according to results from the phase III clinical trial HER2CLIMB-05 presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

$EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy$

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead program EPY201 through Phase 1/2a clinical trials.

10 Dec 2025

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of people with respiratory diseases, today announced the publication of a peer reviewed study in The Journal of Cystic Fibrsosis.

9 Dec 2025

CRISPR-based Cellgorithm technology ushers in a new era of cell programming

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based Cellgorithm technology, which lays the groundwork for programmable control of gene activity in human stem cells and offers an alternative to the slow, variable manual processes researchers use today.

5 Dec 2025

Maximizing bioprocess efficiency through real-time cell density monitoring

Discover how real-time cell density monitoring boosts yield, lowers media costs, and improves viability in bioprocessing.

From Hamilton AG 5 Dec 2025

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

From Rentschler Biopharma SE 2 Dec 2025

AR3-based optogenetic strategy shows high efficacy in inducing apoptosis and antitumor effects

One of the hallmarks of cancer cells is their ability to evade apoptosis, or programmed cell death, through changes in protein expression.

2 Dec 2025

UCI Health launches clinical trial to test investigational cell therapy for lupus

UCI Health has opened a clinical trial to test an investigational cell therapy for lupus with the potential to give patients long-term remission of symptoms.

17 Nov 2025

Advanced workflow automation and scalable image analysis in spatial biology

ZEISS Microscopy and Concept Life Sciences, a UK-based contract research organization (CRO), announced their collaboration aimed at pioneering new approaches to workflow automation and scalable image analysis in spatial biology.

From Concept Life Sciences 26 Sep 2025

Yokogawa and Repligen partner to enhance process analytical technology

Yokogawa Corporation of America and Repligen announce a collaboration to integrate Yokogawa's OpreX Bio Pilot with Repligen's MAVERICK®, enhancing automated control of glucose and lactate levels in cell cultures.

22 Sep 2025

Stem cell therapy shows promise for repairing brain damage after stroke

When someone has a stroke - a leading worldwide cause of death and disability - time is of the essence. Almost nine out of 10 cases are ischemic strokes, caused by restricted blood flow in the brain, and the current gold-standard treatment that breaks up blood clots must be delivered within four and a half hours of symptoms appearing.

16 Sep 2025

Labman leads international project to develop AI-powered bioreactor platform for next-generation biologics

Labman is proud to be involved in a groundbreaking Canada-UK collaboration to revolutionize biopharmaceutical manufacturing using cutting-edge automation, AI, and real-time process control.

From Labman 13 Sep 2025

Redefining BLI: Near-SPR performance built for real-world biologics

Discover how the next-generation technology delivers near-SPR performance tailored for the complexities of real-world biologics.

From Sartorius 19 Aug 2025

Early clinical trial supports MASL as a targeted oral cancer treatment

Rowan University and Sentrimed, a clinical-stage biopharmaceutical company focused on developing safer, orally dosed oncology therapies, today announced results from a National Cancer Institute (NCI) funded clinical trial evaluating MASL in patients with oral squamous cell carcinoma (OSCC).

8 Aug 2025

The Microsphere Summit is Back

Attend the 2025 Microsphere Summit to connect with leaders in drug delivery and manufacturing, focusing on particle size control and therapeutic advancements.

From Powder Systems 5 Aug 2025

$29 million grant funds research on fibrinogen in trauma care

The University of Colorado Anschutz Medical Campus will lead a groundbreaking national clinical trial-supported by a $29 million grant from Octapharma-to evaluate whether early replacement of fibrinogen, a critical blood clotting mechanism in the body, can improve outcomes for trauma patients experiencing life-threatening bleeding.

31 Jul 2025

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, announced today that CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has provided an additional $5.1 M in funding for the development of their lead compound.

29 Jul 2025

Biopharmaceutical News and Research

Addition of tucatinib to the standard of care delays disease progression in HER2-positive metastatic breast cancer

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis

CRISPR-based Cellgorithm technology ushers in a new era of cell programming

Maximizing bioprocess efficiency through real-time cell density monitoring

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

AR3-based optogenetic strategy shows high efficacy in inducing apoptosis and antitumor effects

UCI Health launches clinical trial to test investigational cell therapy for lupus

Advanced workflow automation and scalable image analysis in spatial biology

Yokogawa and Repligen partner to enhance process analytical technology

Stem cell therapy shows promise for repairing brain damage after stroke

Labman leads international project to develop AI-powered bioreactor platform for next-generation biologics

Redefining BLI: Near-SPR performance built for real-world biologics

Early clinical trial supports MASL as a targeted oral cancer treatment

The Microsphere Summit is Back

$29 million grant funds research on fibrinogen in trauma care

Centauri Therapeutics receives an additional $5.1 M from CARB-X to progress ABX-01 lead compound to first in human clinical trials

Common bacterium can turn everyday plastic waste into paracetamol

How Fluidics is Powering Modern Healthcare and Medical Device Innovation

Early gut bacteria may help protect babies from respiratory infections

Event guide: World ADC San Diego eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News